RE:RE:Peak Sales of MCNA and potential.
That is what you thought and were told by management while the share price was evaporating. What shareholders actually knew was that Endo cancelled a trial under mysterious circumstances later said to be recruiting. When Bioniche received the rights to Urocidin back they told shareholders nothing beyond the 3 line abstract presented at the AUA a year or two prior. A few potential sales figures have been batted around since, by both management teams, but no detail or thorough justification was ever provided. Now, assuming that what we hear is true, some light will be shed on what actually went on in P3A and why the FDA has green lighted the submission for approval. I doubt that a medical journal will publish a peer review on those same 3 lines. Substantially more will provided. I am assuming that the FDA was working with more than the 3 line abstract that shareholders have been limited to for 3 plus years. Unfortunately the company had to be nearly destroyed to get to this point.